Literature DB >> 15207826

Paul Ehrlich--in search of the magic bullet.

Florian Winau1, Otto Westphal, Rolf Winau.   

Abstract

In 2004, we celebrate the 150th anniversary of the birth of Paul Ehrlich, considered the founder of immunology. His life and work can be divided into three creative periods: first, he developed histological staining, then he accomplished his ground-breaking work on immunology, and eventually invented chemotherapy. Paul Ehrlich can be perceived as a man whose success was not the consequence of a will to power, but of his substantial interest in science.

Entities:  

Mesh:

Year:  2004        PMID: 15207826     DOI: 10.1016/j.micinf.2004.04.003

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  32 in total

Review 1.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Molecular mechanisms of host-pathogen interactions and their potential for the discovery of new drug targets.

Authors:  Volker Briken
Journal:  Curr Drug Targets       Date:  2008-02       Impact factor: 3.465

Review 3.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

Review 4.  Magnetic nanoparticles in MR imaging and drug delivery.

Authors:  Conroy Sun; Jerry S H Lee; Miqin Zhang
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

5.  THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.

Authors:  Dieter Hörsch; Harshad R Kulkarni; Richard P Baum
Journal:  Ann Transl Med       Date:  2014-01

Review 6.  Current targeted therapies in the treatment of advanced colorectal cancer: a review.

Authors:  Andrew Moriarity; Jacintha O'Sullivan; John Kennedy; Brian Mehigan; Paul McCormick
Journal:  Ther Adv Med Oncol       Date:  2016-05-29       Impact factor: 8.168

7.  Heterobivalent ligands target cell-surface receptor combinations in vivo.

Authors:  Liping Xu; Jatinder S Josan; Josef Vagner; Michael R Caplan; Victor J Hruby; Eugene A Mash; Ronald M Lynch; David L Morse; Robert J Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

Review 8.  Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Authors:  Jacqueline M Benson; David Peritt; Bernard J Scallon; George A Heavner; David J Shealy; Jill M Giles-Komar; Mary Ann Mascelli
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 9.  Silicon micro- and nanofabrication for medicine.

Authors:  Daniel Fine; Alessandro Grattoni; Randy Goodall; Shyam S Bansal; Ciro Chiappini; Sharath Hosali; Anne L van de Ven; Srimeenkashi Srinivasan; Xuewu Liu; Biana Godin; Louis Brousseau; Iman K Yazdi; Joseph Fernandez-Moure; Ennio Tasciotti; Hung-Jen Wu; Ye Hu; Steve Klemm; Mauro Ferrari
Journal:  Adv Healthc Mater       Date:  2013-04-15       Impact factor: 9.933

Review 10.  The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize.

Authors:  Fèlix Bosch; Laia Rosich
Journal:  Pharmacology       Date:  2008-08-05       Impact factor: 2.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.